Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy Against Melanoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 15

PMID 35163049

Authors

Hikaru Nanamori

Yu Sawada

Affiliations

Soon will be listed here.

Abstract

Malignant melanoma is one of the representative skin cancers with unfavorable clinical behavior. Immunotherapy is currently used for the treatment, and it dramatically improves clinical outcomes in patients with advanced malignant melanoma. On the other hand, not all these patients can obtain therapeutic efficacy. To overcome this limitation of current immunotherapy, epigenetic modification is a highlighted issue for clinicians. Epigenetic modification is involved in various physiological and pathological conditions in the skin. Recent studies identified that skin cancer, especially malignant melanoma, has advantages in tumor development, indicating that epigenetic manipulation for regulation of gene expression in the tumor can be expected to result in additional therapeutic efficacy during immunotherapy. In this review, we focus on the detailed molecular mechanism of epigenetic modification in immunotherapy, especially anti-PD-1/PD-L1 antibody treatment for malignant melanoma.

Citing Articles

A375 melanoma-derived lactate controls A375 melanoma phenotypes by inducing macrophage M2 polarization TCA cycle and TGF-β signaling.

Wang Q, Shi Y, Qin Z, Xu M, Wang J, Lu Y PeerJ. 2025; 13:e18887.

PMID: 39995996 PMC: 11849511. DOI: 10.7717/peerj.18887.

Epigenetic modification in radiotherapy and immunotherapy for cancers.

Hung S, Lee M, Chiou W, Liu D, Yu C, Chen L Tzu Chi Med J. 2024; 36(4):396-406.

PMID: 39421493 PMC: 11483092. DOI: 10.4103/tcmj.tcmj_3_24.

New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication.

Qin S, Xie B, Wang Q, Yang R, Sun J, Hu C MedComm (2020). 2024; 5(6):e551.

PMID: 38783893 PMC: 11112485. DOI: 10.1002/mco2.551.

Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1.

Dillen A, Bui I, Jung M, Agioti S, Zaravinos A, Bonavida B Cancers (Basel). 2024; 16(6).

PMID: 38539569 PMC: 10968822. DOI: 10.3390/cancers16061237.

Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers-An Overview.

Mathiyalagan R, Valappil A, Yang D, Kang S, Thambi T Gels. 2022; 8(9).

PMID: 36135270 PMC: 9498739. DOI: 10.3390/gels8090560.

References

Paskeh M, Mehrabi A, Gholami M, Zabolian A, Ranjbar E, Saleki H . EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Biomed Pharmacother. 2021; 146:112532. DOI: 10.1016/j.biopha.2021.112532. View

Sheng W, LaFleur M, Nguyen T, Chen S, Chakravarthy A, Conway J . LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018; 174(3):549-563.e19. PMC: 6063761. DOI: 10.1016/j.cell.2018.05.052. View

Warshaw E, Ruggiero J, DeKoven J, Pratt M, Silverberg J, Maibach H . Patch testing with ammonium persulfate: The North American Contact Dermatitis Group Experience, 2015-2018. J Am Acad Dermatol. 2021; 87(5):1014-1023. DOI: 10.1016/j.jaad.2021.08.005. View

Black J, Manning A, Van Rechem C, Kim J, Ladd B, Cho J . KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell. 2013; 154(3):541-55. PMC: 3832053. DOI: 10.1016/j.cell.2013.06.051. View

Zebertavage L, Alice A, Crittenden M, Gough M . Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity. Sci Rep. 2020; 10(1):7376. PMC: 7193601. DOI: 10.1038/s41598-020-64408-3. View

Patel J, Willis J, Aluri A, Awad S, Smith M, Banker Z . Three-Dimensionally Printed Skin Substitute Using Human Dermal Fibroblasts and Human Epidermal Keratinocytes. Ann Plast Surg. 2021; 86(6S Suppl 5):S628-S631. DOI: 10.1097/SAP.0000000000002886. View

Anderson M, Zhao S, Freud A, Czerwinski D, Kohrt H, Alizadeh A . CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol. 2012; 181(3):795-803. PMC: 3432425. DOI: 10.1016/j.ajpath.2012.05.015. View

Bishop K, Olszewski A . Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer. 2013; 134(12):2961-71. DOI: 10.1002/ijc.28625. View

Sun Z, Allis C . Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature. 2002; 418(6893):104-8. DOI: 10.1038/nature00883. View

10.

Yang G, Zhang G, Pittelkow M, Ramoni M, Tsao H . Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol. 2006; 126(11):2490-506. DOI: 10.1038/sj.jid.5700470. View

11.

Hartana C, Ahlen Bergman E, Broome A, Berglund S, Johansson M, Alamdari F . Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. Clin Exp Immunol. 2018; 194(1):39-53. PMC: 6156818. DOI: 10.1111/cei.13183. View

12.

King J, Patel M, Chandrasekaran S . Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective. Metabolites. 2021; 11(11). PMC: 8620738. DOI: 10.3390/metabo11110792. View

13.

Nunez-Andrade N, Iborra S, Trullo A, Moreno-Gonzalo O, Calvo E, Catalan E . HDAC6 regulates the dynamics of lytic granules in cytotoxic T lymphocytes. J Cell Sci. 2016; 129(7):1305-1311. PMC: 5023047. DOI: 10.1242/jcs.180885. View

14.

Massett M, Monaghan L, Patterson S, Mannion N, Bunschoten R, Hoose A . A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival. Cell Death Dis. 2021; 12(6):573. PMC: 8175737. DOI: 10.1038/s41419-021-03738-0. View

15.

van Steensel B . Mapping of genetic and epigenetic regulatory networks using microarrays. Nat Genet. 2005; 37 Suppl:S18-24. DOI: 10.1038/ng1559. View

16.

Glorieux C, Huang P . CD137 expression in cancer cells: regulation and significance. Cancer Commun (Lond). 2019; 39(1):70. PMC: 6842176. DOI: 10.1186/s40880-019-0419-z. View

17.

Sullivan A, Edlund C, Nord C . Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2002; 1(2):101-14. DOI: 10.1016/S1473-3099(01)00066-4. View

18.

Pastor W, Pape U, Huang Y, Henderson H, Lister R, Ko M . Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011; 473(7347):394-7. PMC: 3124347. DOI: 10.1038/nature10102. View

19.

Mathiot C, Portier A, Brandely M, Galanaud P, Fridman W, Emilie D . Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2. Cancer Immunol Immunother. 1994; 39(1):53-8. PMC: 11038965. DOI: 10.1007/BF01517181. View

20.

Freedman A, Freeman G, Rhynhart K, Nadler L . Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol. 1991; 137(2):429-37. DOI: 10.1016/0008-8749(91)90091-o. View